Epitalon Research

Epitalon is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly, usually written AEDG, and the CAS registry number 307297-39-8, and it also appears in the literature as epithalon and epithalone.

Epitalon is not Epithalamin

Epitalon was designed from the amino acid composition of Epithalamin, a bovine pineal gland extract ^[1]. Epithalamin is an undefined mixture of animal tissue and Epitalon is one defined synthetic molecule, so a result for one is not a result for the other.

The US Food and Drug Administration documented this exact substitution in its 2026 briefing document on epitalon ^[2]. Nominators submitting epitalon for a compounding list supplied 26 articles as evidence, and FDA reported that none discussed epitalon and that seven discussed epithalamin, a different substance ^[2]. The large lifespan and mortality figures circulating under Epitalon's name belong to Epithalamin ^[3] or to the calf thymus extract Thymalin, not to this tetrapeptide.

One research group produced almost all of the literature

Vladimir Khavinson and the St Petersburg Institute of Bioregulation and Gerontology discovered these peptides, patented them, and sell them. Khavinson is a named co-inventor on US patent 6,727,227 B1, which claims the epitalon sequence and is assigned to a company named after his own institute's clinic ^[4]. He also authored most of the supporting research, including the only PubMed-indexed systematic review of this peptide class ^[5]. Papers from the group routinely declare no conflict of interest ^[6]. Read every positive finding below against that background.

Epitalon also sits in a family of nested short peptides, in which Cartalax (AED) is its own first three residues and Cortagen (AEDP) differs from it by one residue ^[7]. That source's own table prints the second name as Korthagen, so searching either spelling will not reliably retrieve it ^[7]. What functionally separates these siblings is not established, beyond one Russian-language animal study in which epitalon reversed induced changes in hypophysectomized chickens and cortagen did not ^[8]. Otherwise the literature is silent, and this page will not invent a difference.

Human evidence

FDA's literature search found three studies in which epitalon has ever been given to humans ^[2].

The strongest is a randomized, placebo-controlled human study in women aged 40 to 50 who worked mainly night shifts and had been screened as having reduced melatonin production ^[2]. Seventy-five were screened, forty met that criterion, and twenty of those then received AEDG as a sublingual spray while twenty received saline, for 20 days ^[2]. Urinary 6-sulfatoxymelatonin rose 1.7-fold in the peptide group and did not change on placebo ^[9]. Blinding was not specified ^[2], and the endpoints were a melatonin metabolite and gene expression, not sleep or any health outcome.

A 2002 report gave epitalon by injection near the eye in patients with retinitis pigmentosa, a route recorded by FDA rather than in the paper's own abstract ^[2]. It claimed a positive clinical effect in 90% of cases, with no sample size and no described control arm in the record ^[10].

FDA found a lack of evidence for effectiveness for insomnia, the only use it evaluated, and no clinical data supporting safety in humans ^[2]. No human pharmacokinetic data exist, so human exposure after any route is unknown, and FDA retrieved no adverse event reports, which reflects absent surveillance rather than safety ^[2].

Animal lifespan work

Mean lifespan was unchanged in the three best-documented rodent studies of this tetrapeptide. In female SHR mice, 54 per group, mean lifespan was unchanged, and the positives were confined to the last 10% of survivors and maximum lifespan ^[11]. Female rats under standard lighting showed no lifespan change ^[12], and in males epitalon "virtually did not change the mean lifespan" ^[13].

The one larger mean effect, 13.5%, came in a cancer-prone transgenic mouse strain that dies of mammary tumors ^[14]. That shows tumor suppression, not slowed aging. The dose in that experiment also sits roughly a thousand times above the one the same group used in its companion study of the same strain ^[15]. No compound in this family has a published NIA Interventions Testing Program evaluation, the multi-site powered standard for rodent lifespan claims ^[16].

Telomeres

The telomere claim rests on two short in vitro reports from the developer group's own institute in St Petersburg. The 2003 paper reports induced hTERT expression, telomerase activity and telomere elongation in human somatic cells ^[17]. The 2004 follow-up reports 10 extra passages, described as overcoming the Hayflick limit ^[18]. Neither abstract carries a sample size or any statistics.

An independent laboratory at Brunel University London reported dose-dependent telomere lengthening in normal human cells in vitro, through hTERT and telomerase upregulation ^[19]. In the breast cancer lines 21NT and BT474, lengthening instead occurred through Alternative Lengthening of Telomeres, specific to the cancer cells ^[19]. Telomere maintenance is a hallmark of malignancy, so that is a safety question, not a benefit, with unknown human implication. The paper also carries a correction stating the wrong figures appeared in Figures 1, 2 and 3 ^[19].

There is no human trial of epitalon with a telomere or telomerase endpoint anywhere in the indexed literature. The closest thing to a human study applied AEDG to lymphocytes from 11 men in a dish, and length changed in 7, rising in 5 and falling in 2 ^[20].

The proposed mechanism

Binding to DNA at gene promoters is a proposal, not a demonstrated mechanism. The founding paper used a complementary binding model and sequence inspection, not a binding experiment ^[21]. The same group later attributed the effects to histone binding instead, again by modelling ^[22]. For epitalon there is no crystal structure, no measured dissociation constant and no chromatin immunoprecipitation. The one experimental NMR study of peptide-DNA binding in this family used the tripeptide Glu-Asp-Arg, not epitalon ^[23].

Regulatory status

Epitalon is not recognized in the European or Japanese Pharmacopoeia, and no approved product contains it in Canada, Australia, the UK or the European Union ^[2]. A US orphan drug designation for retinitis pigmentosa was granted in 2010 and withdrawn in 2016 ^[2]. Designation is not approval, and this one no longer exists. FDA recommended against adding epitalon to the 503A bulk drug substances list ^[2].

Analysts at the Belgian Scientific Institute of Public Health identified epitalon in two illegal pharmaceutical preparations ^[24]. Beyond that letter, none of the work cited here examined a commercially sold preparation, so nothing on this page speaks to the identity or purity of any marketed product.

An independent 2025 review found structural work on epitalon very limited, and the consequence of the proposed DNA binding not known ^[1]. Anisimov, who generated much of the positive rodent data, has written that data on geroprotectors including pineal peptide preparations are "rather scarce, contradictory and are often not reliable" ^[25].

Research-grade Epitalon is supplied as a laboratory research chemical. It is not for human consumption.

Frequently Asked Questions

Is Epitalon the same thing as Epithalamin? No. Epitalon is a defined synthetic tetrapeptide designed from the amino acid composition of Epithalamin, a bovine pineal gland extract ^[1]. FDA has stated that the two are different substances ^[2]. The lifespan and mortality numbers used to market Epitalon come from Epithalamin ^[3] or from the thymus extract Thymalin.

Has Epitalon been tested in humans? Barely. FDA's literature search found three studies in which epitalon was ever given to humans ^[2]. The strongest randomized 40 women screened as having reduced melatonin production ^[2], and measured a urinary melatonin metabolite and gene expression rather than any health outcome ^[9]. No human pharmacokinetic data exist ^[2].

Has the telomere finding been replicated independently? Provisionally, and only in vitro. An independent group at Brunel University London reported telomere lengthening in normal human cells in culture, and also in breast cancer lines through ALT activation ^[19]. That cancer-cell result is a safety question with unknown human implication. The paper also carries a correction covering three of its main figures ^[19], and there is no human telomere trial of epitalon.

References

1. 1

   Araj SK, Brzezik J, Madra-Gackowska K, Szeleszczuk L. Overview of Epitalon. International Journal of Molecular Sciences, 2025;26(6):2691. PMID 40141333.; DOI 10.3390/ijms26062691.
2. 2

   US Food and Drug Administration, Center for Drug Evaluation and Research. Briefing Document, Pharmacy Compounding Advisory Committee, July 2026. https://www.fda.gov/media/193345/download
3. 3

   Anisimov VN, Mylnikov SV, Khavinson VK. Pineal peptide preparation epithalamin increases the lifespan of fruit flies, mice and rats. Mechanisms of Ageing and Development, 1998;103(2):123-132. PMID 9701766.; DOI 10.1016/s0047-6374(98)00034-7.
4. 4

   Khavinson VK, Morozov VG, Malinin VV, Grigoriev EI (inventors). Tetrapetide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application. US Patent 6,727,227 B1, granted 27 April 2004.
5. 5

   Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules, 2021;26(22):7053. PMID 34834147.; DOI 10.3390/molecules26227053.
6. 6

   Khavinson V, Popovich I, Mikhailova O. Acta Biomedica, 2020. PMID 32921699.
7. 7

   Khavinson V, et al. International Journal of Molecular Sciences, 2022;23(14):7733. PMID 35887081.; DOI 10.3390/ijms23147733.
8. 8

   Kuznik BI, et al. Uspekhi Gerontologii / Advances in Gerontology, 2008;21(3):372-381. PMID 19432169. (Russian, English abstract.)
9. 9

   Ivko OM, et al. Uspekhi Gerontologii, 2020;33(3):429-435. PMID 33280326. English translation: Advances in Gerontology, 2021;11(1):53-58, DOI 10.1134/s2079057021010380.
10. 10

    Khavinson V, et al. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuroendocrinology Letters, 2002;23(4):365-368. PMID 12195242.
11. 11

    Anisimov VN, et al. Biogerontology, 2003;4(4):193-202. PMID 14501183.; DOI 10.1023/a:1025114230714.
12. 12

    Vinogradova IA, et al. Bulletin of Experimental Biology and Medicine, 2007;144(6):825-830. PMID 18856211.; DOI 10.1007/s10517-007-0441-z.
13. 13

    Vinogradova IA, et al. Bulletin of Experimental Biology and Medicine, 2008;145(4):472-477. PMID 19110597.; DOI 10.1007/s10517-008-0121-7.
14. 14

    Anisimov VN, et al. Bulletin of Experimental Biology and Medicine, 2002;134(2):187-190. PMID 12459848.; DOI 10.1023/a:1021104819170.
15. 15

    Anisimov VN, et al. International Journal of Cancer, 2002;101(1):7-10. PMID 12209581.; DOI 10.1002/ijc.10570.
16. 16

    Miller RA, et al. Aging Cell, 2007;6(4):565-575. PMID 17578509.; DOI 10.1111/j.1474-9726.2007.00311.x.
17. 17

    Khavinson VKh, Bondarev IE, Butyugov AA. Bulletin of Experimental Biology and Medicine, 2003;135(6):590-592. PMID 12937682.; DOI 10.1023/a:1025493705728.
18. 18

    Khavinson VKh, et al. Bulletin of Experimental Biology and Medicine, 2004;137(5):503-506. PMID 15455129.; DOI 10.1023/b:bebm.0000038164.49947.8c.
19. 19

    Al-Dulaimi S, et al. Biogerontology, 2025;26(5):178. PMID 40908429.; DOI 10.1007/s10522-025-10315-x. Published correction: Biogerontology, 2025;27(1):1. PMID 41240216.; DOI 10.1007/s10522-025-10326-8.
20. 20

    Khavinson VK, et al. Bulletin of Experimental Biology and Medicine, 2019. PMID 31761987.; DOI 10.1007/s10517-019-04664-0.
21. 21

    Khavinson V, et al. Neuroendocrinology Letters, 2005. PMID 15990728. (No DOI assigned.)
22. 22

    Khavinson V, et al. Molecules, 2020;25(3):609. PMID 32019204.; DOI 10.3390/molecules25030609.
23. 23

    Silanteva IA, et al. Role of Mono- and Divalent Ions in Peptide Glu-Asp-Arg-DNA Interaction. Journal of Physical Chemistry B, 2019. PMID 30762356.; DOI 10.1021/acs.jpcb.8b10359.
24. 24

    Vanhee C, et al. Drug Testing and Analysis, 2015;7(3):259-264. PMID 25535022.; DOI 10.1002/dta.1771. (PubMed Letter; no abstract, so the claim rests on the title and the FDA document's citation of it.)
25. 25

    Anisimov VN. Experimental Gerontology, 2001;36(7):1101-1136. PMID 11404054.; DOI 10.1016/s0531-5565(01)00114-0.